Anti-viral Drugs for Hepatitis Regain Center in the Liver Disease Treatment Market

This is when an astounding survey result by World Health Organization indicates that only one out of every 20 hepatitis patients get to know their actual condition. Then there are additional cases when the condition might be acquired from unhealthy lifestyle practices and hyperactive immune system.

As the diagnosed populace continues to increase by multi-million additions each year, the industry veterans in the liver disease treatment market remain highly motivated to expand their product pipelines. So far, 2016 has brought enough good news for the consumer segment; while many more await in near future.

System-assisted Non-Alcoholic Stato-Hepatitis (NASH) therapeutic by Genfit

The novice diagnostic modality is a non-invasive replacement for histological assays. An advanced algorithm detects the extent to which a patient’s liver is affected by the condition based on the net miRNA count in the blood. It maps across the sample to detect the density of miRNA biomarkers. This revolutionary approach has been developed to support Genfit’s blockbuster drug Elafibranor, which is currently under phase III trials.

The company is looking towards unlocking ambitious financial figures to add on to its business value in the NASH segment. With all due credits, if the developers are successful in gaining regulatory approvals by 2020, the company will set its mark of being the first in industry to have commercially placed an integrated treatment module for NASH. The company CEO, Jean-Francois Mouney had earlier announced the collective intention to capture more than a half of the entire market shares by the end of 2020, which is estimated to be around $16 billion.

Investigational oral therapy for hepatitis C

Type C hepatitis claims more lives each year than any other, which brings it under limelight of the liver disease treatment market. The tragic case of this silent epidemic is the fact that by the time its symptoms are visible, most parts of the irreparable damage has been done. Out of the 130 million people affected by hepatitis C virus, 700,000 of them surrender to their condition each year. The unfortunate aspect of this story is that an early diagnosis can help cure 90% of the cases in a mere time span of 90 to 180 days on the calendar.

A couple of years rewound on the current timeline outlines the fallible treatment modalities as adopted by the healthcare professionals. Marked by low success rates and prominent side-effects, those drugs and delivery techniques were highly inefficient. That is when the University of Texas Health Science Center at San Antonio came forward with its revolutionary study-based results. A group of researchers from the institution put forth the findings of a twelve-week long investigation on the effect of a new interferon-free regimen for hepatitis C on cirrhosis patients. It was a short-term treatment that used tolerable agents such as ABT-450/ritonavir, ombitasvir, dasabuvir and ribavirin. Twelve weeks down the lane, more than 91% of the patients were rendered of the hepatitis virus. The net outcome increased by another 4% with an additional 12 weeks of regular dosage.

Late-stage therapies for advanced liver disease treatment are prevalent in the global markets. There exists a promising potential in advanced targeted therapies, and the dominance of immunosuppressants and immunoglobulins. Yet, pharmaceutical giants are inspired by the global healthcare goals and intend to expand their product pipelines in the anti-viral segment. The idea to reduce incidences of new viral hepatitis infections by 90% and deaths due to the same by 60% continues to attract support from experts and funding institutions under WHO’s Global Health Sector Strategy on Viral Hepatitis, 2016-2021.